



PE  
connect<sup>®</sup>

---

POWERED BY COR2ED

# GENETICS OF OBESITY



**Sandro Loche**

SSD di Endocrinologia Pediatrica  
e Centro Screening Neonatale


Ospedale Pediatrico Microcitemico “A. Cao”  
AO Brotzu, Cagliari

# DISCLOSURES



No relevant financial information to disclose


# THE CONCEPT OF ENERGY BALANCE






# THE GENETIC CONTRIBUTION TO OBESITY


Monozygotic twins



Dizygotic twins



# CONTRIBUTION OF PARENTAL AND CHILDHOOD OBESITY TO FUTURE RISK OF OBESITY



CI, confidence interval

Loos RJF, et al. Cell Metab. 2017;25:535-43

# Positional cloning of the mouse *obese* gene and its human homologue

**Yiying Zhang<sup>\*†</sup>, Ricardo Proenca<sup>\*†</sup>, Margherita Maffei<sup>†</sup>, Marisa Barone<sup>\*†</sup>,  
Lori Leopold<sup>\*†</sup> & Jeffrey M. Friedman<sup>\*†‡</sup>**

<sup>\*</sup> Howard Hughes Medical Institute, <sup>†</sup> The Rockefeller University, 1230 York Avenue, New York, New York 10021, USA

Leptin  
from Greek λεπτός  
= lean, skinny



# Congenital leptin deficiency is associated with severe early-onset obesity in humans



Carl T. Montague<sup>\*†</sup>, I. Sadaf Farooqi<sup>\*‡</sup>,  
Jonathan P. Whitehead<sup>\*‡</sup>, Maria A. Soos<sup>\*‡</sup>, Harald Rau<sup>\*‡</sup>,  
Nicholas J. Wareham<sup>§</sup>, Ciaran P. Sewter<sup>\*‡</sup>,  
Janet E. Digby<sup>\*‡</sup>, Shehla N. Mohammed<sup>||</sup>, Jane A. Hurst<sup>§</sup>,  
Christopher H. Cheetham<sup>#</sup>, Alison R. Earley<sup>#</sup>,  
Anthony H. Barnett<sup>☆</sup>, Johannes B. Prins<sup>\*‡</sup>  
& Stephen O'Rahilly<sup>\*‡</sup>

*University of Cambridge, Departments of \* Medicine, ‡ Clinical Biochemistry  
and § Community Medicine, Addenbrooke's Hospital, Hills Road,  
Cambridge CB2 2QR, UK*





# CONGENITAL LEPTIN DEFICIENCY: RESPONSE TO THERAPY




# CONGENITAL LEPTIN DEFICIENCY: RESPONSE TO THERAPY








ACTH, adrenocorticotropic hormone; AGRP, agouti-related peptide; BDNF, brain-derived neurotrophic factor; CLIP, corticotropin-like intermediate peptide; LEPR, leptin receptor; MC4R, melanocortin 4 receptor; MSH, melanocyte-stimulating hormone; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; TrkB, tyrosine kinase receptor B



AgRP, agouti-related peptide; BDNF, brain-derived neurotrophic factor; JAK, janus kinase; LEP, leptin; LEPR, leptin receptor; MC3R, melanocortin 3 receptor; MC4R, melanocortin 4 receptor; MRAP2, melanocortin 2 receptor accessory protein 2; MSH, melanocyte-stimulating hormone; NPY, neuropeptide Y; PC1/3, prohormone convertase 1/3; POMC, pro-opiomelanocortin; SH2B1, Src homology 2 B adaptor protein 1; TrkB, tyrosine kinase receptor B; STAT3, signal transducer and activator of transcription 3



AgRP, agouti-related peptide; BDNF, brain-derived neurotrophic factor; JAK, janus kinase; LEP, leptin; LEPR, leptin receptor; MC3R, melanocortin 3 receptor; MC4R, melanocortin 4 receptor; MRAP2, melanocortin 2 receptor accessory protein 2; MSH, melanocyte-stimulating hormone; NPY, neuropeptide Y; PC1/3, prohormone convertase 1/3; POMC, pro-opiomelanocortin; SH2B1, Src homology 2 B adaptor protein 1; TrkB, tyrosine kinase receptor B; STAT3, signal transducer and activator of transcription 3

Leptin	Rapid weight gain, behavioural problems when food is denied, <b>hyperphagia</b> , hypogonadotropic hypogonadism, defective T-cell mediated immunity, low blood pressure	Autosomal recessive	<i>LEP</i>
Leptin receptor	Rapid weight gain, behavioural problems when food is denied, <b>hyperphagia</b> , hypogonadotropic hypogonadism, defective T-cell mediated immunity, low blood pressure	Autosomal recessive	<i>LEPR</i>
SH2B adaptor protein 1	<b>Hyperphagia</b> childhood onset obesity, insulin resistance, reduced height, behavioural abnormalities	NA	<i>SH2B1</i>
Proopiomelanocortin	Obesity, hypocortisolism, red hair and skin hypopigmentation, neonatal hypoglycaemia, seizures, cholestasis, <b>voracious appetite</b>	Autosomal recessive	<i>POMC</i>
Pro-protein convertase subtilisin / kexin type 1	Early-onset obesity, <b>hyperphagia</b> , postprandial hypoglycaemia, endocrine dysfunction, diarrhoea, diabetes insipidus	Autosomal dominant or recessive	<i>PCSK1</i>
Melanocortin 4 receptor	<b>Hyperphagia</b> rapid weight gain, hyperinsulinaemia, increased linear growth, increase in bone mass, increase in both fat and lean mass	Autosomal dominant or recessive	<i>MC4R</i>

Neurotrophic tyrosine kinase receptor type 2 (tyrosine receptor kinase B)	Early-onset obesity, <b>hyperphagia</b> , developmental delay, impairment in short-term memory, impaired nociception	NA	<i>NTRK2 (TrkB)</i>
Brain-derived neurotrophic factor	<b>Hyperphagia</b> , severe obesity, cognitive impairment, hyperactivity	NA	<i>BDNF</i>
Single-minded homologue 1	<b>Hyperphagia</b> , obesity, reduction in paraventricular nucleus, excessive growth, Prader–Willi like neurobehavioural features	NA	<i>SIM1</i>
Kinase suppressor of Ras 2	<b>Hyperphagia</b> , early-onset obesity, low heart rate, reduced basal metabolic rate, severe insulin resistance	NA	<i>KSR2</i>
Tubby bipartite transcription factor	Deteriorating vision, obesity, normal glucose, cholesterol, triacylglycerols levels	Autosomal recessive	<i>TUB</i>


## Loss-of-function mutations in *ADCY3* cause monogenic severe obesity

Sadia Saeed  <sup>1,2</sup>, Amélie Bonnefond<sup>1</sup>, Filippo Tamanini<sup>2</sup>, Muhammad Usman Mirza  <sup>3</sup>, Jaida Manzoor<sup>4</sup>, Qasim M. Janjua  <sup>5</sup>, Sadia M. Din<sup>6</sup>, Julien Gaitan<sup>7,8</sup>, Alexandra Milochau<sup>7,8</sup>, Emmanuelle Durand<sup>1</sup>, Emmanuel Vaillant<sup>1</sup>, Attiya Haseeb<sup>6</sup>, Franck De Graeve<sup>1</sup>, Iandry Rabearivelo<sup>1</sup>, Olivier Sand<sup>1</sup>, Gurvan Queniat<sup>1</sup>, Raphaël Boutry<sup>1</sup>, Dina A. Schott<sup>9</sup>, Hina Ayesha<sup>10</sup>, Muhammad Ali<sup>11</sup>, Waqas I. Khan<sup>12</sup>, Taeed A. Butt<sup>13</sup>, Tuula Rinne  <sup>14</sup>, Connie Stumpel<sup>15</sup>, Amar Abderrahmani<sup>12</sup>, Jochen Lang  <sup>7,8</sup>, Muhammad Arslan<sup>5,6</sup> and Philippe Froguel  <sup>1,2\*</sup>

## Loss-of-function variants in *ADCY3* increase risk of obesity and type 2 diabetes


Niels Grarup<sup>#1</sup>, Ida Moltke<sup>#2</sup>, Mette K. Andersen<sup>1</sup>, Maria Dalby<sup>2</sup>, Kristoffer Vitting-Seerup<sup>2,3</sup>, Timo Kern<sup>1</sup>, Yuvaraj Mahendran<sup>1</sup>, Emil Jørsboe<sup>2</sup>, Christina V. L. Larsen<sup>4,5</sup>, Inger K. Dahl-Petersen<sup>4</sup>, Arthur Gilly<sup>6</sup>, Daniel Suveges<sup>6</sup>, George Dedoussis<sup>7</sup>, Eleftheria Zeggini<sup>6</sup>, Oluf Pedersen<sup>1</sup>, Robin Andersson<sup>2</sup>, Peter Bjerregaard<sup>4,5</sup>, Marit E. Jørgensen<sup>4,5,8</sup>, Anders Albrechtsen<sup>2</sup>, and Torben Hansen<sup>1,9</sup>

# ADCY3 MUTATIONS: PHENOTYPE





## Subcellular localization of MC4R with ADCY3 at neuronal primary cilia underlies a common pathway for genetic predisposition to obesity

Jacqueline E. Siljee<sup>1</sup>, Yi Wang<sup>1</sup>, Adelaide A. Bernard<sup>1</sup>, Baran A. Ersoy<sup>1,4</sup>, Sumei Zhang<sup>1</sup>, Aaron Marley<sup>2</sup>, Mark Von Zastrow<sup>2</sup>, Jeremy F. Reiter<sup>3</sup> and Christian Vaisse<sup>1\*</sup>




ALMS1, centrosome and basal body associated protein; ADCY3, adenylate cyclase 3; BBSome, complex of Bardet-Biedl syndrome proteins; MC4R, melanocortin 4 receptor

Siljee JE, et al. Nat Genet. 2018;50:180-5

**A****B****C**


## A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction

Karine Clément\*,†‡, Christian Vaisse\*†‡, Najiba Lahliou§,  
Sylvie Cabrol||, Véronique Pelloux\*, Dominique Cassuto\*,  
Micheline Gourmelen||, Christian Dina†, Jean Chambaz†,  
Jean-Marc Lacorte†, Arnaud Basdevant\*†,  
Pierre Bougnères†, Yves Lebouc||, Philippe Froguel\*†  
& Bernard Guy-Grand\*†




## Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by *POMC* mutations in humans

Heiko Krude<sup>1</sup>, Heike Biebermann<sup>1</sup>, Werner Luck<sup>1</sup>, Rüdiger Horn<sup>2</sup>, Georg Brabant<sup>2</sup> & Annette Grüters<sup>1</sup>




### Phenotype:

- Red hair (**MC1R**)
- Adrenal insufficiency (**MC2R**)
- Obesity (**MC4R**)




ACTH, adrenocorticotrophic hormone; CLIP, corticotropin-like intermediate peptide; MC1R, melanocortin 1 receptor; MC2R, melanocortin 2 receptor; MC4R, melanocortin 4 receptor; MSH, melanocyte-stimulating hormone; POMC, pro-opiomelanocortin

- Early onset obesity
- Adrenal insufficiency
- Mental retardation



ACTH, adrenocorticotrophic hormone; CLIP, corticotropin-like intermediate peptide; MSH; melanocyte-stimulating hormone



ACTH, adrenocorticotrophic hormone; CLIP, corticotropin-like intermediate peptide; MSH; melanocyte-stimulating hormone  
 Cirillo G, et al. Br J Dermatol. 2012;167:1393-5


BRIEF REPORT

# Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist


Peter Kühnen, M.D., Karine Clément, M.D., Ph.D., Susanna Wiegand, M.D.,  
Oliver Blankenstein, M.D., Keith Gottesdiener, M.D., Lea L. Martini, M.D.,  
Knut Mai, M.D., Ulrike Blume-Peytavi, M.D., Annette Grüters, M.D.,  
and Heiko Krude, M.D.

July 2016


### A Pretherapy Weight of the Two Patients



### B Patient 1 during Therapy




### C Patient 2 during Therapy



# MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

Karine Clément<sup>1,12</sup>, Heike Biebermann<sup>2,12</sup>, I. Sadaf Farooqi<sup>3,12</sup>, Lex Van der Ploeg<sup>4,12</sup>, Barbara Wolters<sup>2</sup>, Christine Poitou<sup>1</sup>, Lia Puder<sup>2</sup>, Fred Fiedorek<sup>4</sup>, Keith Gottesdiener<sup>4</sup>, Gunnar Kleinau<sup>5</sup>, Nicolas Heyder<sup>6,5</sup>, Patrick Scheerer<sup>5,6</sup>, Ulrike Blume-Peytavi<sup>7</sup>, Irina Jahnke<sup>7</sup>, Shubh Sharma<sup>4</sup>, Jacek Mokrosinski<sup>3</sup>, Susanna Wiegand<sup>8</sup>, Anne Müller<sup>2</sup>, Katja Weiß<sup>9</sup>, Knut Mai<sup>6,10</sup>, Joachim Spranger<sup>10</sup>, Annette Grüters<sup>11</sup>, Oliver Blankenstein<sup>2</sup>, Heiko Krude<sup>2</sup> and Peter Kühnen<sup>2\*</sup>



# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

MARCH 20, 2003

VOL. 348 NO. 12

## Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene

I. Sadaf Farooqi, M.D., Ph.D., Julia M. Keogh, B.Sc., Giles S.H. Yeo, Ph.D.,  
Emma J. Lank, B.Sc., Tim Cheetham, M.D., and Stephen O'Rahilly, M.D.

**Most frequent cause of monogenic obesity**  
**Up to 6% in some studies**

# CHILDREN AND ADOLESCENTS WITH MC4R MUTATIONS DISPLAY A PARTICULAR PHENOTYPE

Autosomal dominant transmission

Hyperphagia

Severe obesity  
(BMI SDS >3)

Early onset of obesity

Tall stature

Hyperinsulinemia

Increased bone mineral density

# PREVALENCE OF MC4R GENE MUTATIONS IN ITALIAN OBESE ADULTS AND CHILDREN



	JCEM '04 <sup>1</sup>	Clin. Chem. '05 <sup>2</sup>	BMC Medical Genetics, 2009 <sup>3</sup>
Number of patients	120	196	240
Age, years +/- SD (range)	12-71	17-70	1-11
Prevalence of mutations, %	1.7	2.5	1.6

Sardinia ≈ 300 children <1%<sup>4</sup>

SD, standard deviation; MC4R, melanocortin 4 receptor

1. Santini F, et al. J Clin Endocrinol Metab. 2004;89:904-8. 2. Buono P, et al. Clin Chem. 2005;51:1358-64. 3. Santoro N, et al. BMC Med Genet. 2009;10:25.

4. Ibba et al., unpublished



## Monogenic obesity

- A single gene mutation causes the disease
- Rare
- Some can be treated



## Syndromic obesity

- At least 20 syndromes
- All rare conditions
- Often associated with mental retardation

# PRADER-WILLI SYNDROME

**Hyperphagia**

**Growth retardation**

**Hypothermia**

**Hypotonia**

**Hypogonadism**

**Nocturnal apnoea**




**Polysomnography**


**Dysmorphism**

**Mental retardation**


**Behavioural problems**



# LOCUS 15q11q13



# PRADER-WILLI SYNDROME: GENETIC MECHANISMS



M, maternal; P, paternal; UPD, uniparental disomy

<http://genetics4medics.com/prader-willi-syndrome.html>. Accessed on January 7, 2020.

# BARDET BIEDL SYNDROME

**Table 1**

Clinical phenotypes associated with ciliopathies

	MKS	BBS	JBTS	JATD	OFD1	MKKS	SLS	NPH	LCA
Retinopathy	+	+	+	-	-	-	+	+	+
Polydactyly	+	+	+	-	+	+	-	-	-
Kidney disease	+	+	+	+	+	-	+	+	-
Situs inversus	+	+	+	-	-	-	+	-	-
Mental retardation/developmental delay	+	+	+	-	+	-	-	+	+
Hypoplasia of cerebellum	+	+	+	-	+	-	-	+	-
Hydrometrocolpos	-	+	-	-	-	+	-	-	-
Obesity	-	+	+	-	-	-	-	-	-
Hepatic dysfunction	+	+	+	-	-	-	+	+	-


JATD, Jeune syndrome; OFD1, orofaciiodigital syndrome 1; MKKS, McKusick-Kaufman syndrome; SLS, Senior-Loken syndrome.

Bardet-Biedl	Mental retardation, retinal dystrophy or pigmentary retinopathy, dysmorphic extremities, hypogonadism, kidney anomalies	1/125,000 to 1/175,000 births	BBS1 (11q13); BBS2 (16q12.2); BBS3 (ARL6, 3q11); BBS4 (15q24.1); BBS5 (2q31.1); BBS6 (MKKS, 20p12); BBS7 (4q27); BBS8 (TTC8, 14q31); BBS9 (PTHB1, 7p14); BBS10 (C12ORF58, 12q21.2); BBS 11 (TRIM32, 9q33.1); BBS12 (FLJ35630, 4q27); BBS13 (MKS1, 17q23); BBS14 (CEP290, 12q21.3); BBS15 (WDPCP, 2p15); BBS16 (SDCCAG8, 1q43); BBS17 (LZTFL1, 3p21); BBS18 (BBIP1, 10q25); BBS19 (IFT27, 22q12)
--------------	---	-------------------------------	---

BBS, Bardet Biedl syndrome; JATD, Jeune syndrome; JBTS, Joubert syndrome; LCA, Leber congenital amaurosis; OFD1, orofaciiodigital syndrome 1; MKKS, McKusick-Kaufman syndrome; MKS, Meckel-Gruber syndrome; NPH, nephronophthisis; SLS, Senior-Loken syndrome.

## Subcellular localization of MC4R with ADCY3 at neuronal primary cilia underlies a common pathway for genetic predisposition to obesity

Jacqueline E. Siljee<sup>1</sup>, Yi Wang<sup>1</sup>, Adelaide A. Bernard<sup>1</sup>, Baran A. Ersoy<sup>1,4</sup>, Sumei Zhang<sup>1</sup>, Aaron Marley<sup>2</sup>, Mark Von Zastrow<sup>2</sup>, Jeremy F. Reiter<sup>3</sup> and Christian Vaisse<sup>1\*</sup>



ALMS1, centrosome and basal body associated protein; ADCY3, adenylate cyclase 3; BBSome, complex of Bardet-Biedl syndrome proteins; MC4R, melanocortin 4 receptor

Siljee JE, et al. Nat Genet. 2018;50:180-5



## Monogenic obesity

- A single gene mutation causes the disease
- Rare
- Some can be treated

## Syndromic obesity

- At least 20 syndromes
- All rare conditions
- Often associated with mental retardation




## Polygenic obesity

- ~30% of obese children have  $\geq 1$  obese parent
- Common condition!
- Overall 40-60% of the obesity susceptibility is due to genetic influences






# POLYGENIC OBESITY



Is the result of the interaction of a combination of different genetic susceptibility variants in different chromosomes with a permissive environment




BMI, body mass index; FTO, fat mass and obesity-associated gene

Goodarzi MO. Lancet Diabetes Endocrinol. 2018;6:223-36

# FTO IS A DNA DEMETHYLASE



**Genetic effect: Homozygous for the most significantly associated SNP carry 1.67 higher risk of developing obesity**




FTO, fat mass and obesity-associated gene; SNP, single nucleotide polymorphism


Willer CJ, et al. Nat Genet. 2009;41:25-34

# FTO IN 912 OBESE CHILDREN AND ADOLESCENTS FROM SARDINIA

Patients



Controls



FTO (rs9939609)		Patients		Controls		Odds ratio	95% CI	$\chi^2$	P value
		Observed	Frequency	Observed	Frequency				
N. samples		912		543					
Allele A		1000	0.55	466	0.43	1.6	1.3–1.8	35.5	$<1 \times 10^{-5}$
Allele T		824	0.45	620	0.57				
Individuals AA		285	0.31	106	0.20				
Individuals AT		430	0.47	254	0.47				
Individuals TT		197	0.22	183	0.34				

Homozygous for the A variant have 1.6 increased risk to develop obesity

---

## Overexpression of *Fto* leads to increased food intake and results in obesity

Chris Church<sup>1</sup>, Lee Moir<sup>1</sup>, Fiona McMurray<sup>1</sup>, Christophe Girard<sup>2</sup>, Gareth T Banks<sup>1</sup>, Lydia Teboul<sup>1</sup>, Sara Wells<sup>1</sup>, Jens C Brüning<sup>3</sup>, Patrick M Nolan<sup>1</sup>, Frances M Ashcroft<sup>2</sup> & Roger D Cox<sup>1</sup>



## Loss-of-Function Mutation in the Dioxygenase-Encoding *FTO* Gene Causes Severe Growth Retardation and Multiple Malformations

Sarah Boissel,<sup>1,7</sup> Orit Reish,<sup>2,7</sup> Karine Proulx,<sup>3,7</sup> Hiroko Kawagoe-Takaki,<sup>4</sup> Barbara Sedgwick,<sup>4</sup>  
Giles S.H. Yeo,<sup>3</sup> David Meyre,<sup>5</sup> Christelle Golzio,<sup>1</sup> Florence Molinari,<sup>1</sup> Noman Kadhom,<sup>1</sup>  
Heather C. Etchevers,<sup>1</sup> Vladimir Saudek,<sup>3</sup> I. Sadaf Farooqi,<sup>3</sup> Philippe Froguel,<sup>5,6</sup> Tomas Lindahl,<sup>4</sup>  
Stephen O'Rahilly,<sup>3</sup> Arnold Munnich,<sup>1</sup> and Laurence Colleaux<sup>1,\*</sup>

**8 cases described**  
**All died in the first three years of life**

# Prevalence of Loss-of-Function *FTO* Mutations in Lean and Obese Individuals

David Meyre,<sup>1</sup> Karine Proulx,<sup>2</sup> Hiroko Kawagoe-Takaki,<sup>3</sup> Vincent Vatin,<sup>1</sup> Ruth Gutiérrez-Aguilar,<sup>1</sup> Debbie Lyon,<sup>3</sup> Marcella Ma,<sup>2</sup> Helene Choquet,<sup>1</sup> Fritz Horber,<sup>4</sup> Wim Van Hul,<sup>5</sup> Luc Van Gaal,<sup>6</sup> Beverley Balkau,<sup>7</sup> Sophie Visvikis-Siest,<sup>8</sup> François Pattou,<sup>9</sup> I. Sadaf Farooqi,<sup>2</sup> Vladimir Saudek,<sup>2</sup> Stephen O'Rahilly,<sup>2</sup> Philippe Froguel,<sup>1,10</sup> Barbara Sedgwick,<sup>3</sup> and Giles S.H. Yeo<sup>2</sup>



TABLE 3

Summary of nonsynonymous mutations unique to the lean or the obese group


Nonsynonymous mutations	<i>n</i>
Obese subjects	
A134T	1
G187A	2
M223V	1
A241T	2
H419R	1
E471G	1
I492V	1
V493F	1
Prevalence of mutations (%)	0.91
Lean subjects	
P5L	1
E24K	1
R80P	1
P93R	1
V94I	1
N143S	1
I148R	1
D189N	1
E234D	1
R316Q	1
P399H	1
Prevalence of mutations (%)	0.77

ORIGINAL ARTICLE

# An Obesity-Associated FTO Gene Variant and Increased Energy Intake in Children

Joanne E. Cecil, Ph.D., Roger Tavendale, Ph.D., Peter Watt, Ph.D.,  
Marion M. Hetherington, Ph.D., and Colin N.A. Palmer, Ph.D.

Jane Wardle, Susan Carnell, Claire M. A. Haworth, I. Sadaf Farooqi, Stephen O'Rahilly,  
and Robert Plomin




A/X, heterozygous carriers; TT, noncarriers

Cecil JE, et al. N Engl J Med. 2008;359:2558-66

Anastasia Ibba, Sabrina Pilia, Patrizia Zavattari, Alberto Loche, Chiara Guzzetti,  
Maria Rosaria Casini, Luigi Minerba and Sandro Loche\*





## The role of *FTO* genotype on eating behavior in obese Sardinian children and adolescents



# FTO Obesity Variant Circuitry and Adipocyte Browning in Humans

Melina Claussnitzer, Ph.D., Simon N. Dankel, Ph.D., Kyoung-Han Kim, Ph.D., Gerald Quon, Ph.D., Wouter Meuleman, Ph.D., Christine Haugen, M.Sc., Viktoria Glunk, M.Sc., Isabel S. Sousa, M.Sc., Jacqueline L. Beaudry, Ph.D., Vijitha Puvindran, B.Sc., Nezar A. Abdennur, M.Sc., Jannel Liu, B.Sc., Per-Arne Svensson, Ph.D., Yi-Hsiang Hsu, Ph.D., Daniel J. Drucker, M.D., Gunnar Mellgren, M.D., Ph.D., Chi-Chung Hui, Ph.D., Hans Hauner, M.D., and Manolis Kellis, Ph.D.





# COMPLICATIONS OF OBESITY

Insulin  
resistance/  
Type II diabetes

Dyslipidaemia

Liver steatosis  
(NAFLD)

Tumours

Hypertension

Cardiovascular  
complications

Review

EASL | JOURNAL OF  
HEPATOLOGY


2013

## A 360-degree overview of paediatric NAFLD: Recent insights

Valerio Nobili<sup>1,\*</sup>, Gianluca Svegliati-Baroni<sup>2</sup>, Anna Alisi<sup>1</sup>, Luca Miele<sup>3</sup>, Luca Valenti<sup>4</sup>, Pietro Vajro<sup>5</sup>

**Overweight and obesity are consistently indicated as the most significant risk factors for the development of NAFLD. About 25% of obese children have increased ALT.**

# PREVALENCE OF NAFLD IN OUR COHORT OF 410 OBESE CHILDREN AND ADOLESCENTS



	Gruppo 1	Gruppo 2	p-value
Età (anni±DS)	11.77±2.94	10.24±3.27	0,0008
Sesso (maschi/femmine)	29/23	172/358	
Prepuberi/puberi	20/32	211/147	
BMI-SDS	2.72±0.44	2.64±0.52	0.11
Glicemia (mg/dl)	90.23±6.24	89.05±8.11	0.17
Colesterolo totale	165.10±20.73	171.5±30.35	0.15
Colesterolo HDL	50.54±13.12	53.10±13.51	0.09
Colesterolo LDL	99.94±27.32	104.2±27.37	0.29
Trigliceridi	74.50±45.16	69.51±42.06	0.74
AST	28.77±8.68	23.99±5.99	<0.0001
ALT	37.29±22.42	22.12±9.72	<0.0001
HOMA-IR	4.09±2.65	2.8±2.2	<0.0001


ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HDL, high-density lipoprotein cholesterol; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; SDS, standard deviation score


# SNPs REPRODUCIBLY ASSOCIATED WITH PEDIATRIC FATTY LIVER DISEASE

Gene	SNP	Function	Hepatic Fat	Circulating Lipids
<i>PNPLA3</i>	rs738409	Remodeling of lipid droplets	↑	↔
<i>GCKR</i>	rs1260360	Modulation of hepatic lipogenesis	↑	↑
<i>TM6SF2</i>	rs58542926	Modulation lipoprotein secretion	↑	↓

*GCKR*: Glucokinase Regulatory Protein; *PNPLA3*: Patatin-like phospholipase domain-containing 3; *TM6SF2*: Transmembrane 6 Superfamily Member 2; SNP: Single Nucleotide Polymorphism.

# ADIPONUTRIN-LIKE PHOSPHOLIPASE-3 GENE (PNPLA3) IS EXPRESSED IN THE LIVER AND ADIPOSE TISSUE IT CAN BOTH SYNTHESIZE AND HYDROLYSE TRIGLYCERIDES






**Fig. 1. Association between *PNPLA3* I148 M (rs738409) and transaminase levels in a cohort of obese children and adolescents (*n* = 475).** Mean plasma levels  $\pm$  standard deviations of (A) alanine transaminase (ALT) and (B) aspartate transaminase (AST) stratified by *PNPLA3* genotype. *p*-values are calculated using linear regression including age, gender, BMI, and Tanner stage as covariates. (C) Distribution of obese children and adolescents with pathological levels of circulating alanine transferase (ALT) in the different *PNPLA3* genotypes. ALT >30 U/L was classified as elevated. The *p* value is calculated from  $\chi^2$ . II = individuals with two I 148 alleles, MM = individuals with two M alleles, IM heterozygotes.

II, individuals with two I 148 alleles, ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; IM, heterozygotes; MM, individuals with two M alleles; *PNPLA3*, adiponutrin-like phospholipase-3 gene

# EPIGENETICS AND OBESITY




# OBESITY: A POLYGENIC, EPIGENETIC AND MULTIFACTORIAL DISEASE

## Spotlight

### Non-Genetic Transmission of Obesity – It's in Your Epigenes


Elena Loche<sup>1</sup> and  
Susan E. Ozanne<sup>1,\*</sup>

Obesity and its related metabolic comorbidities can be inherited across generations through non-genetic mechanisms. In a recent report, Huypens *et al.*, using an *in vitro* fertilization approach, provide evidence that exposure to a high-fat diet modifies egg and sperm epigenetic information, rendering the progeny more prone to obesity.



## Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood

### Graphical Abstract



### Authors

Amit V. Khera, Mark Chaffin,  
Kaitlin H. Wade, ..., Nicholas J. Timpson,  
Lee M. Kaplan, Sekar Kathiresan

### Correspondence

avkhera@mgh.harvard.edu (A.V.K.),  
skathiresan1@mgh.harvard.edu (S.K.)

### In Brief

A genome-wide polygenic score quantifies inherited susceptibility to obesity, integrating information from 2.1 million common genetic variants to identify adults at risk of severe obesity.

# POLYGENIC PREDICTION OF WEIGHT AND OBESITY TRAJECTORIES



A genome-wide polygenic score can quantify inherited susceptibility to obesity




Polygenic score effect on weight emerges early in life and increases into adulthood



Effect of polygenic score can be similar to a rare, monogenic obesity mutation



High polygenic score is a strong risk factor for severe obesity and associated diseases





[Sandro.loche@aob.it](mailto:Sandro.loche@aob.it)  
[Endocrinologia.pediatrica@aob.it](mailto:Endocrinologia.pediatrica@aob.it)